TISACID (a new, modern Hungarian Al-containing
antacid) with a high
acid-neutralizing capacity (greater than 26.8 mmol/g) also enhances gastric mucosal defense mechanisms (
prostaglandin-dependent gastroprotection). A simple-blind, prospective, randomized, parallel multicentre clinical trial has been performed on both the clinical efficacy and possible side effects of
TISACID monotherapy (Al-Mg-hydroxy-
carbonate) on informed patients suffering from active
duodenal ulcers. The study groups were as follows: Group "A": 3 g/day of
TISACID (
acid-neutralizing capacity = 78 mmol, n = 85), Group "B": 6 g/day of
TISACID (
acid-neutralizing capacity = 156 mmol, n = 88), Group "C": 12 g/day of
TISACID (
acid-neutralizing capacity = 312 mmol, n = 68), Group "D": (as control): (1.0 g/day
cimetidine (
HISTODIL, RGH, Budapest, n = 91). The total number of patients: 332. It was found that: 1. The new Hungarian
antacid compound (both
tablet and
suspension) can essentially accelerate the healing rate of
duodenal ulcers. 2. The cumulative healing rate of
ulcers and the decrease of complaints can be achieved equally by relatively low doses of
TISACID monotherapy and
cimetidine alone. 3. There were no differences between the clinical potency and side-effects of
TISACID tablet and
suspension.